Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. (Q51231723)

From Wikidata

Jump to navigation Jump to search

scientific article published on 4 April 2006

Language	Label	Description	Also known as
English	Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.	scientific article published on 4 April 2006

Statements

scholarly article

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. (English)

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

author name string

Aaron N Nguyen

1

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Elizabeth G Stebbins

2

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Margaret Henson

3

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Gilbert O'Young

4

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Sun J Choi

5

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Diana Quon

6

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Debby Damm

7

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Mamatha Reddy

8

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Jing Y Ma

9

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Edwin Haghnazari

10

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Ann M Kapoun

11

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Satyanarayana Medicherla

12

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Andy Protter

13

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

George F Schreiner

14

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Noriyoshi Kurihara

15

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Judy Anderson

16

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

G David Roodman

17

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Tony A Navas

18

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Linda S Higgins

19

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

language of work or name

0 references

publication date

4 April 2006

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Experimental Cell Research

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

312

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

1909-1923

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

10

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Pathogenesis and management of bone lesions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Drug resistance and drug development in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

The tumor microenvironment: focus on myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

New insights into role of microenvironment in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Advances in biology of multiple myeloma: clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

The tumor microenvironment as a determinant of drug response and resistance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Map kinase signaling pathways and hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Adhesion mechanisms regulating the migration of monocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Regulation of osteoclast function

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Bisphosphonate Induced Growth Inhibition of Breast Cancer Cells is Augmented by p38 Inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Bone morphogenetic proteins, their antagonists, and the skeleton

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Wnt signaling in osteoblasts and bone diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Multiple myeloma: evolving genetic events and host interactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Cancer and the microenvironment: myeloma-osteoclast interactions as a model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Anti-myeloma activity of pamidronate in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Identifiers

10.1016/J.YEXCR.2006.02.026

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51231723&oldid=1370620069"